The pharmaceutical company JSC Farmak (Kyiv) has received a request from the Ministry of Health and scientists regarding the possibility of its involvement in clinical trials of a Ukrainian vaccine against COVID-19, the company has told Interfax-Ukraine.
“Farmak has recently received a request from the Ministry of Health and scientists about the possibility of involving the company in clinical trials of the Ukrainian vaccine against COVID-19. Also, the state received a request for the possibility of industrial production of the vaccine (if its safety and effectiveness are proved),” the company said.
Currently, Farmak is studying the request: the company’s experts are analyzing the available materials related to the development and are consulting with scientists and representatives of the Ministry of Health.
As reported, the state intends to fund clinical trials of the vaccine.
Farmak manufactures medicines in all fourteen therapeutic groups. Among the main directions are anti-cold, endocrinological, gastroenterological, cardiological, neurological portfolios. The company annually introduces to the market about 20 new complex-component modern drugs, and about 100 drugs are currently in development.
Over the past five years, Farmak’s investments in the scientific and technical complex, production equipment, and research activities amounted to UAH 3.4 billion.
In 2019, Farmak received a net profit of UAH 1.056 billion, which is almost the same as in 2018 at UAH 1.05 billion, while in 2018 Farmak increased its net profit by 25.16%.
JSC Farmak is a member of the Manufacturers of Medications of Ukraine Association.
According to the unified state register of legal entities and individual entrepreneurs, the ultimate beneficial owner of Farmak is the head of the supervisory board, Filya Zhebrovska, who owns 80% of the company’s shares.